COMMUNIQUÉS West-GlobeNewswire

Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
11/10/2026
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically [...]
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
11/10/2026
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure
11/10/2026
In Cycle-1 REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with HFrEF on top of guideline-directed medical therapy, with a favorable [...]
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
11/10/2026
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 - 100% of participants who received encaleret reported improvements in at least one ADH1 [...]
Beyond Cholesterol Numbers: Dr. Wallace Brucker Brings AI-Powered Cardiac Plaque Screening to Las Vegas Executives at LV Longevity Lab
11/10/2026
LAS VEGAS, NV, Oct. 11, 2026 (GLOBE NEWSWIRE) -- Using FDA-cleared Cleerly AI analysis of coronary CT angiography, LV Longevity Lab looks directly at the arteries — settling whether plaque exists and personalizing [...]
Claris Biotherapeutics Releases Positive CSB-001 Clinical Proof-of-Concept Data in Limbal Stem Cell Deficiency at AAO 2026 Annual Meeting
11/10/2026
41% of CSB-001 treated eyes gained ≥15 letters compared to 0% in the non-treatment arm 55% of CSB-001 treated eyes gained ≥10 letters compared to 5% in the non-treatment arm Responses were durable, with 50% and 81% of [...]
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
11/10/2026
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of colorectal cancer [...]
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
10/10/2026
In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks 1,2 UME is the leading cause of moderate and severe [...]
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
10/10/2026
NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that [...]
Corza Medical Launches Expanded Blink Single-Use Custom Packs and First-of-Its-Kind Microsurgical Knife Manufacturing Process
10/10/2026
BOULDER, Colo., Oct. 10, 2026 (GLOBE NEWSWIRE) -- Corza Medical, a leading global medical technology company, today announced the launch of its expanded Blink Single-Use Custom Packs offering and a first-of-its-kind [...]
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
10/10/2026
New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems HIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a [...]
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
10/10/2026
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across injection sites [...]
RadiusXR and Topcon Healthcare Inc. Introduce InspirePRO: The New Standard in Visual Field Testing
09/10/2026
RadiusXR and Topcon Healthcare, Inc. unveil InspirePRO at AAO: the full measurement range expertly engineered into a lightweight wearable experience. Purpose-built medical-grade perimeter combines comprehensive glaucoma [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
09/10/2026
Lakewood, Colo., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
09/10/2026
Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: [...]
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
09/10/2026
Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) ( [...]
J-Star Holding Co., Ltd. Highlights Capital Initiatives to Fund Planned U.S. Expansion for Drone Frame Manufacturing in Houston, Texas
09/10/2026
HOUSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (NASDAQ: YMAT) (“J-Star” or the “Company”), an advanced composite manufacturing innovator, today announced that its ongoing corporate capital [...]
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
09/10/2026
SAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public [...]
AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
09/10/2026
ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) [...]

Pages